Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,netReceivables,inventory,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,changeToNetincome,changeToInventory,changeToAccountReceivables,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,GBLX,-4143452.0,293520992,,,-629621,,-593984,670311,0,-670311,-670311,,-167120,,,,206690,0,670311,0,40690,242327,-836311,-593984,1647376.0,98126152.0,12744924.0,-2496076.0,1942925.0,10248848.0,28382.0,2084877.0,-100650610.0,3429704.0,5677156.0,771064.0,9031278.0,369445.0,28150.0,2896166.0,283942.0,1456695.0,,,-241920.0,3996963.0,-2756014.0,-2729521.0,-301385.0,98605.0,227116.0,-1040326.0,14485.0,4322963.0,-72112.0,-152164.0,,,,-6135112.0,en-US,US,EQUITY,False,Delayed Quote,0.039,1630521873,0.001000002,0.037,0.039,0.0334,465376,USD,PNK,11447319,-14400000,False,False,POST,4,2.6315844,0.0334 - 0.039,us_market,0,GB SCIENCES INC,0.038,0.0,0.0,0,0,finmb_260598993,Other OTC,"GB Sciences, Inc.",USD,330053,694183,0.019000001,0.9500001,0.02 - 0.13,-0.09099999,-0.6999999,0.02,0.13,1598612340,1598612340,1598612340,-0.045,-0.009,0.04611111,-0.00711111,-0.15421684,0.05731884,-0.01831884,-0.31959543,-4.3333335,15,America/New_York,EDT,0.22,,,0.13,0.02,0.0461,0.0573,330.05k,694.18k,293.52M,,270.73M,7.86%,0.00%,,,,,,,,,,,0.00%,,,1:10,"Oct 30, 2013","Mar 30, 2020","Dec 30, 2020",0.00%,-143.78%,-18.00%,-473.85%,3.12M,0.01,,-881.46k,-4.35M,-13.76M,-0.0450,,771.06k,0,4.34M,,0.32,-0.01,-1.48M,-294.75k,Value,89118-6876,Healthcare,23,"GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.",Las Vegas,866 721 0297,NV,1609372800,United States,http://www.gbsciences.com,86400,3550 West Teco Avenue,Biotechnology
t-1,GBLX,-3894926.0,293520992,,,-904514,,-805458,491818,0,-491818,-491818,,-410946,,,,19034,0,491818,0,-412696,118090,-923548,-805458,1545355.0,97679001.0,16603635.0,-2349571.0,1968967.0,14254064.0,28054.0,1997037.0,-100056626.0,3465160.0,5766598.0,545020.0,13138475.0,,31278.0,6910833.0,,2346652.0,4350000.0,,0.0,3996963.0,-2756014.0,-2729521.0,-301385.0,98605.0,227116.0,-1040326.0,14485.0,4322963.0,-72112.0,-152164.0,,,,-6227642.0,en-US,US,EQUITY,False,Delayed Quote,0.039,1630521873,0.001000002,0.037,0.039,0.0334,465376,USD,PNK,11447319,-14400000,False,False,POST,4,2.6315844,0.0334 - 0.039,us_market,0,GB SCIENCES INC,0.038,0.0,0.0,0,0,finmb_260598993,Other OTC,"GB Sciences, Inc.",USD,330053,694183,0.019000001,0.9500001,0.02 - 0.13,-0.09099999,-0.6999999,0.02,0.13,1598612340,1598612340,1598612340,-0.045,-0.009,0.04611111,-0.00711111,-0.15421684,0.05731884,-0.01831884,-0.31959543,-4.3333335,15,America/New_York,EDT,0.22,,,0.13,0.02,0.0461,0.0573,330.05k,694.18k,293.52M,,270.73M,7.86%,0.00%,,,,,,,,,,,0.00%,,,1:10,"Oct 30, 2013","Mar 30, 2020","Dec 30, 2020",0.00%,-143.78%,-18.00%,-473.85%,3.12M,0.01,,-881.46k,-4.35M,-13.76M,-0.0450,,771.06k,0,4.34M,,0.32,-0.01,-1.48M,-294.75k,Value,89118-6876,Healthcare,23,"GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.",Las Vegas,866 721 0297,NV,1609372800,United States,http://www.gbsciences.com,86400,3550 West Teco Avenue,Biotechnology
t-2,GBLX,-3425158.0,293520992,,,-1837860,,-1846700,804708,59402,-745306,-745306,,-795313,,,,8840,551197,1296503,491795,-1092554,118090,-1846700,-1846700,1776045.0,97574001.0,16022755.0,-1649113.0,601822.0,14373642.0,28054.0,,-99251168.0,,91504.0,101230.0,12502644.0,362838.0,5384983.0,7121110.0,,2712122.0,5416932.0,1545891.0,72280.0,3996963.0,137228.0,273309.0,641703.0,151202.0,-50536.0,-323845.0,13028.0,4322963.0,-15121.0,282331.0,64602.0,-70814.0,,-5381534.0,en-US,US,EQUITY,False,Delayed Quote,0.039,1630521873,0.001000002,0.037,0.039,0.0334,465376,USD,PNK,11447319,-14400000,False,False,POST,4,2.6315844,0.0334 - 0.039,us_market,0,GB SCIENCES INC,0.038,0.0,0.0,0,0,finmb_260598993,Other OTC,"GB Sciences, Inc.",USD,330053,694183,0.019000001,0.9500001,0.02 - 0.13,-0.09099999,-0.6999999,0.02,0.13,1598612340,1598612340,1598612340,-0.045,-0.009,0.04611111,-0.00711111,-0.15421684,0.05731884,-0.01831884,-0.31959543,-4.3333335,15,America/New_York,EDT,0.22,,,0.13,0.02,0.0461,0.0573,330.05k,694.18k,293.52M,,270.73M,7.86%,0.00%,,,,,,,,,,,0.00%,,,1:10,"Oct 30, 2013","Mar 30, 2020","Dec 30, 2020",0.00%,-143.78%,-18.00%,-473.85%,3.12M,0.01,,-881.46k,-4.35M,-13.76M,-0.0450,,771.06k,0,4.34M,,0.32,-0.01,-1.48M,-294.75k,Value,89118-6876,Healthcare,23,"GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.",Las Vegas,866 721 0297,NV,1609372800,United States,http://www.gbsciences.com,86400,3550 West Teco Avenue,Biotechnology
t-3,GBLX,-1788460.0,293520992,,,-8541507,,-8628345,1269952,-60516,-1330468,-1330468,,-292567,,,,86837,784115,2114583,844631,-7211039,118090,-8628344,-8628345,1699966.0,97271157.0,14441362.0,-88494.0,592982.0,14352868.0,27554.0,,-97387205.0,,91504.0,151766.0,10885757.0,355516.0,5560518.0,7000880.0,,2559914.0,5342390.0,1445839.0,303676.0,3996963.0,154038.0,345888.0,785685.0,204815.0,114466.0,-231422.0,35480.0,4322963.0,-12965.0,6562580.0,321649.0,-108067.0,-16000.0,-3884877.0,en-US,US,EQUITY,False,Delayed Quote,0.039,1630521873,0.001000002,0.037,0.039,0.0334,465376,USD,PNK,11447319,-14400000,False,False,POST,4,2.6315844,0.0334 - 0.039,us_market,0,GB SCIENCES INC,0.038,0.0,0.0,0,0,finmb_260598993,Other OTC,"GB Sciences, Inc.",USD,330053,694183,0.019000001,0.9500001,0.02 - 0.13,-0.09099999,-0.6999999,0.02,0.13,1598612340,1598612340,1598612340,-0.045,-0.009,0.04611111,-0.00711111,-0.15421684,0.05731884,-0.01831884,-0.31959543,-4.3333335,15,America/New_York,EDT,0.22,,,0.13,0.02,0.0461,0.0573,330.05k,694.18k,293.52M,,270.73M,7.86%,0.00%,,,,,,,,,,,0.00%,,,1:10,"Oct 30, 2013","Mar 30, 2020","Dec 30, 2020",0.00%,-143.78%,-18.00%,-473.85%,3.12M,0.01,,-881.46k,-4.35M,-13.76M,-0.0450,,771.06k,0,4.34M,,0.32,-0.01,-1.48M,-294.75k,Value,89118-6876,Healthcare,23,"GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.",Las Vegas,866 721 0297,NV,1609372800,United States,http://www.gbsciences.com,86400,3550 West Teco Avenue,Biotechnology
